Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02095587 · ClinicalTrials.gov registry record · Phase 1
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
A Phase 1 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02095587 is a Phase 1 study that has completed, run by SecuraBio. The registered enrollment target is 24 participants.
The verdict
NCT02095587, a Phase 1 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to subjects with chronic hepatic impairment and in matched healthy subjects.
Interventions
- DRUG IPI-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02095587
The ClinicalTrials.gov registry entry for NCT02095587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-145 is the first listed.
NCT02095587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02095587 about?
NCT02095587 is a clinical study titled "Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects". To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to subjects with chronic hepatic impairment and in matched healthy subjects.
What is the current status of trial NCT02095587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-03. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02095587?
The interventions under investigation include: IPI-145 (DRUG).
Who is sponsoring clinical trial NCT02095587?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.